TMSP(SH:600671)2020-06-11 16:00Financial Performance - Operating revenue for the reporting period was CNY 55.72 million, representing a decline of 26.40% year-on-year[5] - Net profit attributable to shareholders of the listed company was a loss of CNY 3.17 million, an improvement from a loss of CNY 3.30 million in the same period last year[5] - The weighted average return on net assets was -0.0233%, improving from -3.3881% in the same period last year[5] - The basic and diluted earnings per share were both -CNY 0.0002, compared to -CNY 0.0154 in the previous year[5] - Total operating revenue for Q1 2020 was ¥55,721,624.55, a decrease of 26.5% compared to ¥75,708,330.55 in Q1 2019[38] - Net loss for Q1 2020 was ¥351,748.20, an improvement from a net loss of ¥1,005,525.92 in Q1 2019[39] - The company's gross profit margin decreased to -6.0% in Q1 2020 from -3.8% in Q1 2019[39] - Total comprehensive income for Q1 2020 was CNY 431,573.56, compared to CNY 132,534.73 in Q1 2019, representing a significant increase[44] - Basic and diluted earnings per share for Q1 2020 were CNY 0.0035, up from CNY 0.0011 in Q1 2019, indicating a growth of 218.18%[44] Cash Flow - The net cash flow from operating activities was a negative CNY 326,267.54, compared to a positive CNY 38.75 million in the previous year, indicating a significant decline[5] - Net cash flow from operating activities decreased by 100.84% to -¥326,267.54 from ¥38,750,738.27, primarily due to the absence of demolition compensation received in the current period[12] - Cash inflow from operating activities totaled CNY 61,556,795.15 in Q1 2020, down 44.83% from CNY 111,776,527.56 in Q1 2019[45] - Cash outflow from operating activities was CNY 61,883,062.69 in Q1 2020, a decrease of 15.38% compared to CNY 73,025,789.29 in Q1 2019[45] - Net cash flow from investing activities was negative CNY 6,120,608.55 in Q1 2020, worsening from negative CNY 932,586.70 in Q1 2019[45] - Cash inflow from financing activities was CNY 95,000,000.00 in Q1 2020, significantly higher than CNY 22,802,985.62 in Q1 2019, marking an increase of 316.67%[45] - Cash outflow from financing activities totaled CNY 94,371,761.04 in Q1 2020, compared to CNY 82,362,180.49 in Q1 2019, reflecting an increase of 14.56%[45] - The ending cash and cash equivalents balance for Q1 2020 was CNY 19,889,615.27, down from CNY 64,813,183.49 in Q1 2019, a decrease of 69.32%[45] - The company reported a net decrease in cash and cash equivalents of CNY 5,818,637.13 in Q1 2020, compared to a decrease of CNY 21,741,043.30 in Q1 2019[45] Assets and Liabilities - Total assets at the end of the reporting period were approximately CNY 525.13 million, a decrease of 2.15% compared to the end of the previous year[5] - Current assets totaled ¥221,036,919.25, down from ¥235,623,141.87, indicating a decrease of about 6.2%[30] - Total liabilities were reported at ¥384,782,876.00, down from ¥395,967,943.52, reflecting a decrease of approximately 2.7%[32] - Non-current liabilities increased to ¥201,649,742.52 from ¥190,792,915.56, indicating an increase of about 5.0%[32] - Short-term borrowings rose to ¥48,000,000.00 from ¥38,000,000.00, marking an increase of approximately 26.3%[31] - The total equity attributable to shareholders was ¥105,998,979.30, a slight decrease from ¥106,023,673.98[32] Shareholder Information - The total number of shareholders at the end of the reporting period was 16,649[9] - The top shareholder, Changcheng Film and Television Culture Group Co., Ltd., held 30,181,813 shares, accounting for 24.78% of the total shares[9] Government Subsidies and Investments - The company received government subsidies amounting to CNY 3.01 million, which were closely related to its normal business operations[8] - The total non-recurring gains and losses for the period amounted to CNY 3.15 million[9] - The company plans to invest ¥14 million in the establishment of the Xishuangbanna Great Wall Health Industry Park, holding a 9.33% stake[13] - The company plans to invest CNY 75 million in GMP transformation for its new production lines to ensure the sales of its leading products, Pearl Eye Drops and Amoxicillin Clavulanate Tablets[18] Contracts and Compensation - The company has signed a major engineering contract worth ¥60 million, exceeding 50% of its net assets[14] - The company has received ¥203,918,492.00 in compensation for the relocation of its pharmaceutical center, with a total compensation agreement of ¥210,918,492.00[17] Outstanding Loans - The company has outstanding loans totaling CNY 24.6 million from its controlling shareholder and related parties, which remain unpaid as of the report date[24] - The controlling shareholder committed to resolving the CNY 24.6 million fund occupation issue by December 31, 2019, but this has not been fulfilled[25] Future Outlook - The company anticipates a potential net loss for the year, contrasting with a net profit of CNY 3.036 million in the same period last year, primarily due to government compensation received from land acquisition[26]